Dataset from An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of Three Different Treatment Regimens of 2 mg Aflibercept Administered by Intravitreal Injections to Subjects With Diabetic Macular Edema (DME)

To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different
intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg
aflibercept every 8 weeks after 5 initial monthly injections for approximately 1 year or more
(according to the EU label for the first year of treatment)